The Association for Cancer Immunotherapy
CIMT is a member-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. Founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine, CIMT operates as an independent non-profit organization and is financed by donations, congress fees, industry sponsorship, and public and foundation grants. CIMT organizes Europe's largest specialty meeting on cancer immunotherapy research, translation, and development.
For more information on the Association for Cancer Immunotherapy, please go to www.cimt.eu
CODES OF PRACTICE
CIMT is committed to complying with the codes of practice governing the interactions between the industry and healthcare professionals and organizations. For this reason, all companies and associations exhibiting at CIMT are advised to consult the guidelines and codes of practice applicable in Germany. By signing the relevant application form, each company or organization agrees to and confirms that it has reviewed the advice and guidelines which determine the applicable codes of practice in Germany, and that it will adhere to all relevant codes and will accept full liability for all cases of non-compliance with these codes.
COPYRIGHT AND IMAGE RIGHTS
By participating in the CIMT Annual Meeting, all registered attendees agree to adhere to the Copyright and Image Rights of the 16th CIMT Annual Meeting.
2018 CIMT Annual Meeting
Scientific Planning Committee
TRON-Translational Oncology, Mainz/Germany; CIMT Scientific Secretary
Eli Lilly, New York, NY/USA
Sine Reker Hadrup
Denmark Technical University, Copenhagen/Denmark
Leiden University Medical Center, Leiden/The Netherlands
Paul-Ehrlich-Institute (PEI), Langen/Germany
TRON-Translational Oncology, Mainz/Germany; Head CIMT Management Board